Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Salivary gland cancer
Results 1-25 of 71 for your search:
Start Over
Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1216, NCI-2013-00500, NCT01810913
Acupuncture in Treating Dry Mouth Caused by Radiation Therapy in Patients with Head and Neck Cancer
Phase: Phase III
Type: Supportive care
Age: Not specified
Trial IDs: 97115, NCI-2011-02073, CDR0000674208, WF 97115, WFU-97115, MDA-04-01, NCT01141231
Dapsone Gel, 5% in Reducing Rash in Patients with Metastatic Colorectal Cancer or Head and Neck Cancer Undergoing Chemotherapy with Cetuximab
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 13-012, NCI-2013-01729, NCT01931150
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-048, NCI-2015-00270, 2014-003698-41, NCT02358031
Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients with Head and Neck Cancer Undergoing Radiation Therapy
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: ENT0042, NCI-2015-00176, 351, NCT02369835
Cetuximab, EGFR Antisense DNA, and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 06-121, NCI-2013-00329, NCT00903461
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients with Cancer Receiving Anti-Angiogenesis Therapy
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: VARIMG0002, NCI-2013-00535, NCT01806675
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-1972, NCI-2013-00586, NCT01816984
Iressa Study in Patients With Salivary Gland Cancer
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2004-0089, NCI-2010-00744, NCT00509002
Dynasplint Trismus System or Tongue Depressors in Reducing Trismus in Patients With Previously Treated Head and Neck Cancer
Phase: Phase II
Type: Supportive care
Age: 20 and over
Trial IDs: UAB0780, NCI-2011-03029, HNO 0602, NCT00507208
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 15309, NCI-2009-01492, NCT01044433
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Phase: Phase II
Type: Educational/Counseling/Training, Supportive care
Age: 11 to 24
Trial IDs: ANUR1131, NCI-2012-00682, CDR0000726664, COG-ANUR1131, NCT01556256
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 7674, NCI-2012-00892, NCT01613768
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4193C00003, NCI-2015-00612, NCT02319044
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Cisplatin with or without WEE1 Inhibitor MK-1775 in Treating Patients with Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: PHL-088, NCI-2014-00759, NCI 9416, NCT01935037, 9416, NCT02196168
Vaccinia Virus in Treating Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: 06-041, NCI-2011-02461, NCT00574977
Autologous Cytotoxic T Lymphocytes in Treating Patients With Advanced HER2- Positive Malignancy
Phase: Phase I
Type: Treatment
Age: 3 and over
Trial IDs: H-24486, NCI-2012-00777, NCT00889954
Dose-escalation Study of Oral CX-4945
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C4-08-001, NCI-2009-01571, NCT00891280
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-078, NCI-2011-02511, CDR0000689900, NCT01249443
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 10-115, NCI-2011-02500, CDR0000700997, 8808, NCT01366144
Start Over